Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 ubiquitin-protein ligase TRIM15 is a cytoplasmic enzyme belonging to the tripartite motif (TRIM) family, characterized by three zinc-binding domains (RING finger, B-box type 1, B-box type 2) and a coiled-coil region[1][2][3]. TRIM15 acts as an E3 ubiquitin ligase, regulating the ubiquitin-proteasome pathway to control protein degradation. It promotes cell proliferation and metastasis in various cancers by targeting substrates such as Keap1 for proteasomal degradation, thereby modulating key cellular pathways including the Nrf2 antioxidant pathway and ERK1/2 signaling[2][3][5]. TRIM15 also functions in innate immunity, contributing to interferon induction and viral defense by modulating pathways like RIG-I-MAVS and interacting with focal adhesion components to regulate cell migration and chemotaxis[3][6][7]. Its dysregulation has been linked to oncogenesis, making it a potential therapeutic target, especially in lung, melanoma, and pancreatic cancers[2][5].
Ubiquitination and proteasomal degradation of substrate proteins; activation of MAPK/ERK pathway; degradation of Keap1 to activate Nrf2 pathway
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E3 ubiquitin-protein ligase TRIM15 (TRIM15).